Tositumomab Side Effects
Applies to tositumomab: intravenous kit.
Very common (10% or more): Rash, pruritus
Common (1% to 10%): Sweating[Ref]
Common (1% to 10%): Hypothyroidism[Ref]
Very common (10% or more): Positive serology for human anti-mouse antibodies (HAMA)[Ref]
Frequency not reported: Infusion reactions[Ref]
Very common (10% or more): Myalgia, arthralgia
Common (1% to 10%): Dizziness, somnolence
Postmarketing reports: Axonal neuropathy leading to quadriparesis[Ref]
Common (1% to 10%): Secondary malignancies (non-melanoma skin, colorectal, head and neck, breast, lung, bladder, melanoma, gastric)
Common (1% to 10%): Pneumonia[Ref]
More about tositumomab
Related treatment guides
1. "Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab)." GlaxoSmithKline (2022):
2. "Product Information. BexxarTherapy (tositumomab)." GlaxoSmithKline Inc (2006):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.